Different pro-angiogenesis ability of bone marrow mesenchymal stem cells in multiple myeloma in active and remissive state
10.3969/j.issn.2095-4344.2014.37.006
- VernacularTitle:骨髓间充质干细胞在多发性骨髓瘤活动与缓解期具有不同的促血管生成能力
- Author:
Xiangli LI
;
Xiaoying ZHANG
;
Li ZANG
;
Xiaofang WANG
- Publication Type:Journal Article
- Keywords:
bone marrow;
mesenchymal stem cells;
multiple myeloma;
cellmovement
- From:
Chinese Journal of Tissue Engineering Research
2014;(37):5935-5941
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Recent studies have found that bone marrow mesenchymal stem cells play an important role in the development of multiple myeloma, especial y for angiogenesis, but whether the pro-angiogenesis ability of bone marrow mesenchymal stem cells in multiple myeloma in active and remissive state is different is yet unclear. OBJECTIVE:To investigate the difference in the pro-angiogenesis ability of bone marrow mesenchymal stem cells in multiple myeloma in active and remissive state. METHODS:Bone marrow samples were extracted from 13 patients with multiple myeloma before treatment and after four therapeutic cycles to isolate bone marrow mesenchymal stem cells. ELISA assay was used to detect levels of vascular endothelial growth factor, hepatocyte growth factor and basic fibroblast growth factor in the supernatant of bone marrow mesenchymal stem cells. The proliferative ability and movement of human umbilical vein endothelial cells cultured in the supernatant of bone marrow mesenchymal stem cells were detected by MTT assay and Transwel assay, respectively. The pro-angiogenesis ability of bone marrow mesenchymal stem cells was measured by Matrigel in vitro. RESULTS AND CONCLUSION:The levels of vascular endothelial growth factor, hepatocyte growth factor and basic fibroblast growth factor in the cellsupernatant were significantly higher in active myeloma than those in remissive myeloma (P<0.05). The supernatant of bone marrow mesenchymal stem cells of active myeloma more significantly promoted the proliferation, migration and blood vessel formation of human umbilical vein endothelial cells than that of remissive myeloma in a dose-dependent manner (P<0.05). These findings indicate that bone marrow mesenchymal stem cells from active myeloma have stronger pro-angiogenesis ability than those from remissive myeloma.
